about
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domainsEntry of pseudotyped hepatitis C virus into primary human hepatocytes depends on the scavenger class B type I receptorHepatitis C virus hijacks host lipid metabolismSystemic manifestations of hepatitis C infectionTight Junctions Go Viral!CD81 and Claudin 1 Coreceptor Association: Role in Hepatitis C Virus EntrySubcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vectorIdentification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing AntibodiesHuman occludin is a hepatitis C virus entry factor required for infection of mouse cellsIdentification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C VirusIdentification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA ReplicationThe Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the MoleculeCrystal structure of glycoprotein E2 from bovine viral diarrhea virusLipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomesCD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cellsPersistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell cultureMechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidolHuman monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzeesAn integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infectionA Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus.Thematic minireview series: elucidating hepatitis C virus-host interactions at the biochemical level.Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantationHepatitis C virus experimental model systems and antiviral drug research.Development of hepatitis C virus vaccines: challenges and progress.Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assayTupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.Experimental models for hepatitis C viral infection.New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agentsAdaptive immunity to hepatitis C virus.Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study.Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein.The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapyRole of lipid metabolism in hepatitis C virus assembly and entry.Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation.Multifaceted roles for lipids in viral infection.Cholesterol and chronic hepatitis C virus infection.Hepatitis C virus: a new class of virus associated with particles derived from very low-density lipoproteins.Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.
P2860
Q21089621-00388784-1E55-469D-AEBD-90779DEC36FFQ24336433-2DE3AAB3-E59E-454B-A4F0-08CDD29D7695Q24652319-8BC4305C-E3A2-423F-828D-E79C2571A1CDQ26746040-C1497DC5-0A57-4769-91B7-FB2FF0744F7AQ26781335-3C5B425C-0049-408B-8882-F43E755EDD28Q27485899-BC9FEA97-BB2E-49E1-86E2-AD31EABFC265Q27486946-7385A9BA-E84F-471A-A802-BFE147C982CBQ27487399-4906EA38-DA56-4FBE-86D9-83FB35C2E7E1Q27490169-6C9084D5-9757-434E-AC3C-46B277557C98Q27490467-1A482E95-8D95-43E1-ACB1-6F2A5801A05AQ27490525-49FEDFAD-30FB-4A93-BC9A-6F2FBDC538BDQ27490948-3F90E577-2A7B-4AB7-A20C-ECDADBEDFDECQ27677276-DED44A94-4CCD-40EF-AA05-8CC446F61345Q28081216-0A2D7D11-EAD7-462F-9DDC-5C2D8BF7BBA8Q28114859-E6C93B90-D63B-4CC7-89A6-B2D1E0211294Q28473992-230785F3-853B-4AFB-9B40-C8CF71044E63Q28476811-AF50AB52-05A3-4D77-9F0E-DCD6F8B05B38Q28483065-81FF7D78-EA7D-4908-B56F-E6DC6626C9C5Q28743482-AA0097AF-2B43-4149-8E76-5DA7DA0CF004Q33648339-B13802B5-DEB4-4E0C-8866-86DFA483C9CDQ33863096-7F28A7FA-F857-4E13-A657-874BBCFCA7BBQ34003751-6E2FE59D-32B1-4162-96B7-F909B95ED43AQ34096483-B8B02838-2B58-4CB3-BEA7-E6808D85993BQ34235286-F69601E5-48B7-45BB-99B5-C26F0CF71109Q34254941-C90A2901-F4AF-4ED7-AAFA-96F23B22B799Q34403294-039F9AB0-C5BB-4E2F-9364-C94B4FCDA3FFQ34742966-D5879350-D951-480D-A38A-B080854A3BA1Q34996679-1F53560E-15FC-49B0-94B1-D048043A84D1Q35026553-ED0144E9-D847-4B85-A473-EDCCCACF5FFBQ35259748-CF1C1D18-FA8F-4C87-9FC8-638ED9AC41FAQ36904033-5E88785E-20D3-482D-B8C2-AFEEDAB9B926Q37263829-8E306675-A091-4CC6-A927-F725B4CBD155Q37609487-64E12DCB-C0C1-4E8F-AAD2-B4E0458F6ECEQ37609988-4D4B9FA3-787B-4CF3-80E9-C72D017C1DBEQ37621569-32EC8A10-87B0-48A0-94A3-0F96C1D901B8Q37864742-78DC6FD4-223B-4EAE-94BB-76DFCDBB5B59Q37870334-36C2704D-C73D-4C64-98A2-7AFF1ECD5B96Q37891171-D33E6C6C-B1F4-4EB8-89BF-4A90AD751139Q38003914-2256EC71-A2C3-430C-A7D2-00028C312F11Q38223279-C2663D62-E082-4C69-B666-19C2102823B0
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Hepatitis C virus entry.
@en
type
label
Hepatitis C virus entry.
@en
prefLabel
Hepatitis C virus entry.
@en
P2860
P356
P1476
Hepatitis C virus entry.
@en
P2093
Charles M Rice
Thomas von Hahn
P2860
P304
P356
10.1074/JBC.R700024200
P407
P577
2007-09-19T00:00:00Z